文献速递皮肤肿瘤

31基因表达谱检测在86例AJCC IB-II期黑色素瘤患者中的早期预后表现:前瞻性多中心队列研究

Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-02-28

中位随访26个月(IQR 22-30),7例(8.1%)发生转移且均属Class 2组(占该组21.2%)。多因素Cox回归校正AJCC分期和年龄后,该检测是复发的独立预后因素,提示其可识别早期分期中高复发风险患者。

要点

  • 31基因表达谱可将IB-II期黑色素瘤患者分为低风险Class 1和高风险Class 2。
  • 本队列中所有7例转移患者均位于Class 2组,占该组21.2%。
  • 校正AJCC分期和年龄后,该检测为复发的独立预后因素。

核心结论

  • 在西班牙白种人前瞻性多中心队列中,31基因表达谱检测可正确识别早期AJCC分期中复发风险较高的患者。
  • 基因表达谱与AJCC分期系统联合可能改善需强化监测患者的检出并优化随访策略。

研究设计与样本

  • 共86例患者完成31基因表达谱检测,所有患者前瞻性随访以评估复发风险。
  • 采用Kaplan-Meier曲线和Cox回归分析评估无病生存的预后准确性,检测结果分为Class 1(低风险)和Class 2(高风险)。

主要发现

  • 中位随访时间26个月(IQR 22-30)。
  • 86例中7例发生转移(8.1%),全部位于Class 2组,占该组的21.2%。
  • 多因素Cox回归分析校正AJCC分期和年龄后,基因表达谱是复发的独立预后因素。

关键数值与推荐

  • 31基因表达谱(DecisionDx-Melanoma)检测结果分为Class 1(低风险)和Class 2(高风险)。

临床怎么用

  • 对于AJCC IB-II期黑色素瘤患者,可考虑使用31基因表达谱检测辅助识别高复发风险者。
  • 基因表达谱结果可与AJCC分期系统结合,用于优化随访策略和强化监测决策。

局限性

  • 随访时间较短,中位随访仅26个月。
  • 样本量较小,共86例患者。
  • 研究人群为西班牙白种人队列,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical and pathological features of primary melanoma are not sufficiently sensitive to accurately predict which patients are at a greater risk of relapse. Recently, a 31-gene expression profile (DecisionDx-Melanoma) test has shown promising results. OBJECTIVES: To evaluate the early prognostic performance of a genetic signature in a multicentre prospectively evaluated cohort. METHODS: Inclusion of patients with AJCC stages IB and II conducted between April 2015 and December 2016. All patients were followed up prospectively to assess their risk of relapse. Prognostic performance of this test was evaluated individually and later combined with the AJCC staging system. Prognostic accuracy of disease-free survival was determined using Kaplan-Meier curves and Cox regression analysis. Results of the gene expression profile test were designated as Class 1 (low risk) and Class 2 (high risk). RESULTS: Median follow-up time was 26 months (IQR 22-30). The gene expression profile test was performed with 86 patients; seven had developed metastasis (8.1%) and all of them were in the Class 2 group, representing 21.2% of this group. Gene expression profile was an independent prognostic factor for relapse as indicated by multivariate Cox regression analysis, adjusted for AJCC stages and age. CONCLUSIONS: This prospective multicentre cohort study, performed in a Spanish Caucasian cohort, shows that this 31-gene expression profile test could correctly identify patients at early AJCC stages who are at greater risk of relapse. We believe that gene expression profile in combination with the AJCC staging system could well improve the detection of patients who need intensive surveillance and optimize follow-up strategies.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Podlipnik S, Carrera C, Boada A, et al. Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study. J Eur Acad Dermatol Venereol. 2019. PMID: 30702163. doi:10.1111/jdv.15454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。